Ovarian and cervical cancer patient derived xenografts: The past, present, and future.

@article{Boone2015OvarianAC,
  title={Ovarian and cervical cancer patient derived xenografts: The past, present, and future.},
  author={Jonathan D. Boone and Zachary C. Dobbin and John Michael Straughn and Donald J Buchsbaum},
  journal={Gynecologic oncology},
  year={2015},
  volume={138 2},
  pages={486-91}
}
Preclinical research in gynecologic malignancies has largely relied upon cloned cancer-derived cell lines and tumor xenografts derived from these cell lines. Unfortunately, the use of cell lines for translational research has disadvantages because genetic and phenotypic alterations from serial passaging have resulted in expression profiles that are different from the original patient tumors. The patient-derived xenograft (PDX) model derived from human tumor not previously cultured has shown… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 75 references

An ex vivo assay of XRTinduced Rad 51 foci formation predicts response to PARPinhibition in ovarian cancer

  • B. Ali, E. Wang, S. Patra
  • Gynecol . Oncol .
  • 2014

E

  • M. D. Topp, L. Hartley, M. Cook, V. Heong
  • Boehm, et al., Molecular correlates of platinum…
  • 2014
2 Excerpts

M

  • M. M. Shah, Z. C. Dobbin, S. Nowsheen
  • Wielgos, A.A. Katre, et al., An ex vivo assay of…
  • 2014

Similar Papers

Loading similar papers…